{
    "nct_id": "NCT00000177",
    "title": "Estrogen Hormone Protocol",
    "status": "COMPLETED",
    "last_update_time": "2009-12-10",
    "description_brief": "Estrogen is a hormone that is dominant in the female reproductive system. In women, most estrogen is produced by the ovaries. Men produce estrogen by converting testosterone into estrogen. Because this hormone also has many beneficial effects on brain cells, it currently is being studied as a treatment for Alzheimer's disease. The enzyme that forms the neurotransmitter acetylcholine is promoted in the presence of estrogen. Several very small clinical studies have demonstrated improvement in cognitive function and mood measures in women with Alzheimer's disease who take estrogen.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Estrogen (examples used in trials: 17\u03b2\u2011estradiol; conjugated equine estrogens [CEE])"
    ],
    "placebo": [
        "Not specified in the description"
    ],
    "explanation_target": [
        "Reason: The description states estrogen is being studied as a treatment for Alzheimer's because it has beneficial effects on brain cells (promotes the enzyme that forms acetylcholine) and small clinical studies showed cognitive and mood improvements \u2014 this indicates the intervention is intended to improve cognition rather than directly target core AD pathology (amyloid or tau).",
        "Act: The titled trial 'Estrogen Hormone Protocol' (NCT00000177) is a hormone therapy trial of estrogen for Alzheimer disease (trial listing). \ue200cite\ue202turn0search4\ue201",
        "Act (evidence \u2014 clinical trials and mechanism): Small randomized trials have tested unopposed conjugated equine estrogens (CEE) and transdermal 17\u03b2\u2011estradiol for cognition in women with AD. Mechanistic/neurochemical studies show estradiol increases choline acetyltransferase activity and other markers of cholinergic function. \ue200cite\ue202turn0search3\ue202turn0search8\ue202turn0search2\ue201",
        "Act (broader evidence/risks): Large prevention trials (WHIMS) showed no dementia prevention benefit and in some analyses increased dementia risk in older postmenopausal women treated with CEE (important context but does not change the intended cognitive-enhancing classification). \ue200cite\ue202turn0search7\ue201",
        "Reflect: Given estrogen is a steroid hormone (a small molecule), but the trial's intent (improve cognition/mood via cholinergic/neuroprotective effects) fits the 'cognitive enhancer' category rather than a disease-targeted biologic or a small molecule aimed specifically at amyloid/tau pathology. There is some ambiguity because estrogen may have neuroprotective effects, but available descriptions emphasize symptomatic cognitive/mood improvement, so 'cognitive enhancer' is the best match.",
        "Web-search sources consulted: MedPath trial listing for 'Estrogen Hormone Protocol' (NCT00000177). \ue200cite\ue202turn0search4\ue201; Randomized trial of conjugated equine estrogens in women with AD. \ue200cite\ue202turn0search3\ue201; WHIMS large study on CEE and dementia risk. \ue200cite\ue202turn0search7\ue201; Transdermal 17\u03b2-estradiol trial showing short-term cognitive effects. \ue200cite\ue202turn0search8\ue201; Preclinical/biochemical studies showing estradiol increases choline acetyltransferase and cholinergic markers. \ue200cite\ue202turn0search2\ue202turn0search6\ue201"
    ],
    "agent_type": "L) Growth Factors and Hormones",
    "explanation_agent": [
        "Reason: The trial tests estrogen (17\u03b2\u2011estradiol or conjugated equine estrogens) as a hormone therapy intended to improve cognition/mood via effects on brain cells and cholinergic function (e.g., increased choline acetyltransferase), rather than directly targeting core AD proteinopathies such as amyloid\u2011\u03b2 or tau. \ue200cite\ue202turn1search0\ue202turn0search3\ue201",
        "Act: Extracted details \u2014 title 'Estrogen Hormone Protocol' (NCT00000177), intervention = estrogen (examples used in trials: 17\u03b2\u2011estradiol; conjugated equine estrogens/CEE). Small randomized trials tested CEE or transdermal 17\u03b2\u2011estradiol for cognition in women with AD, and mechanistic studies report estradiol increases ChAT and other cholinergic markers. \ue200cite\ue202turn1search0\ue202turn0search9\ue202turn0search7\ue201",
        "Act (broader clinical evidence): Larger prevention/older-women trials (WHIMS) showed no dementia prevention benefit and in pooled analyses an increased dementia risk with CEE (and with CEE+MPA), an important safety/contextual finding but not changing the mechanistic classification. \ue200cite\ue202turn0search2\ue202turn0search1\ue201",
        "Reflect: Mapping to CADRO \u2014 estrogen is a hormone and fits the CADRO category L) Growth Factors and Hormones. Although estrogen exerts downstream effects on neurotransmitter systems (cholinergic enhancement) and may have neuroprotective/neurotrophic actions, the primary biological class is hormone therapy rather than a direct anti\u2011amyloid or anti\u2011tau agent; therefore L is the most specific CADRO match. Supporting sources: trial listing and mechanistic/clinical literature above. \ue200cite\ue202turn1search0\ue202turn0search3\ue202turn0search2\ue201",
        "Web search results used (key citations): MedPath trial listing for 'Estrogen Hormone Protocol' (NCT00000177). \ue200cite\ue202turn1search0\ue201; Randomized trial of CEE in women with AD. \ue200cite\ue202turn0search9\ue201; Preclinical studies showing estradiol increases choline acetyltransferase (ChAT). \ue200cite\ue202turn0search3\ue202turn0search7\ue201; WHIMS findings on CEE (and CEE+MPA) and dementia risk. \ue200cite\ue202turn0search2\ue202turn0search1\ue201"
    ]
}